Alteplase for the management of occluded central venous access devices: safety considerations.
Smith
Lisa Hartkopf
LH
Riverside Methodist Hospital, Columbus, OH, USA. lsmith2@ohiohealth.com
D002405:Catheterization, Central Venous / Q000009:adverse effects*; D017277:Drug Approval; D016903:Drug Monitoring / Q000451:nursing; D004868:Equipment Failure; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D017410:Practice Guidelines as Topic; D017751:Safety Management / Q000458:organization & administration*; D018805:Sepsis / Q000139:chemically induced / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator